[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644840":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":29,"locations":38,"responsibleParty":57,"collaborators":25,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":67,"sex":68,"minAge":69,"maxAge":25,"enrollmentInfo":70,"targetDuration":25,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":40,"whyStopped":25,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Cedars-Sinai Medical Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Fisetin","EXPERIMENTAL","Participants receive oral fisetin at approximately 20 mg\u002Fkg\u002Fday for 2 consecutive days on Days 1-2 and again on Days 8-9 using a senolytic \"hit-and-run\" dosing strategy.",[13],"Drug: Fisetin",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Participants receive matching placebo capsules administered on the same schedule as the fisetin arm (Days 1-2 and Days 8-9).",[19],"Drug: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Participants randomized to the experimental arm will receive oral fisetin capsules administered at a target dose of approximately 20 mg\u002Fkg\u002Fday for 2 consecutive days on Days 1-2 and again on Days 8-9. Fisetin will be supplied as 100 mg capsules and dosed according to body weight using a senolytic \"hit-and-run\" treatment approach.",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Participants randomized to the control arm will receive matching placebo capsules administered orally on the same schedule as the fisetin arm (Days 1-2 and Days 8-9). Placebo will be used to maintain blinding and permit comparison of efficacy and safety outcomes between treatment groups.",[15],[30,35],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Samuel Cohen, MD","CONTACT","310-423-1725","samuel.cohen@csmc.edu",{"name":36,"role":32,"phone":25,"phoneExt":25,"email":37},"Yunhee Choi-Kuaea","Yunhee.Choi-Kuaea@cshs.org",[39],{"facility":5,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"RECRUITING","Los Angeles","California","90048","United States","US",{"type":47,"coordinates":48},"Point",[49,50],-118.24368,34.05223,{"lat":50,"lon":49},[53,55],{"name":36,"role":32,"phone":25,"phoneExt":25,"email":54},"yunhee.choi-kuaea@cshs.org",{"name":31,"role":56,"phone":25,"phoneExt":25,"email":25},"PRINCIPAL_INVESTIGATOR",{"type":56,"investigatorFullName":31,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Assistant Professor of Medicine","100644840","phase-2-ongoing-lung-decline-with-age-intensified-response-100644840",false,"NCT07676435","Ongoing Lung Decline With Age Intensified Response","A PHASE II, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE ONGOING LUNG DECLINE WITH AGE INTENSIFIED RESPONSE (OLD AIR)","OLD AIR","Inclusion Criteria:\n\n* Adults aged 60 years and older who are physically capable of participating in study procedures;\n* Willing to be randomized to fisetin or placebo; weight stable within the previous 2 months (\\\u003C5-pound change);\n* No blood donation within 2 months before screening; absence of unstable chronic disease;\n* Willing to maintain baseline activity level throughout the study;\n* Body mass index \\\u003C30 kg\u002Fm²;\n* Either a history of at least 10 pack-years of cigarette smoking or never-smoking status.\n\nExclusion Criteria:\n\n* Electrocardiogram (ECG) abnormalities, including prolonged QTc.\n* Use of fisetin, other flavonoid supplements, or known senolytic compounds within 6 months prior to screening.\n* Resting systolic blood pressure \\>160 mmHg or diastolic blood pressure \\>110 mmHg.\n* Known allergy or hypersensitivity to fisetin or any component of the study product.\n* Active malignancy, except non-melanoma skin cancer.\n* Clinically significant hepatic, renal, cardiovascular, endocrine, immunologic, metabolic, or other uncontrolled medical conditions that, in the opinion of the investigator, would interfere with study participation or interpretation of results.\n* Clinically significant laboratory abnormalities, including severe anemia, leukopenia, thrombocytopenia, uncontrolled diabetes, advanced kidney disease, significant liver dysfunction, or evidence of systemic inflammation.\n* Human immunodeficiency virus (HIV) infection, active hepatitis B or hepatitis C infection, or invasive fungal infection.\n* History of diverticulitis or diverticulosis with gastrointestinal bleeding.\n* Current use of systemic corticosteroids.\n* Current use of warfarin.\n* Current use of medications with significant interaction potential with fisetin, including selected CYP450 or transporter substrates, inhibitors, or inducers, unless such medications can be safely withheld according to protocol requirements.\n* Recent medication, supplement, or lifestyle changes that may affect study outcomes, in the opinion of the investigator.\n* Inability to perform required study procedures, including pulmonary function testing, exercise testing, or other protocol assessments.\n* Unwillingness or inability to provide informed consent.\n* Pregnancy or breastfeeding.\n* Any other condition that, in the opinion of the investigator, would make participation unsafe or compromise study integrity.",true,"ALL","60 Years",{"count":71,"type":72},40,"ESTIMATED","INTERVENTIONAL",[75],"PHASE2","This Phase II, randomized, double-blind, placebo-controlled pilot study will evaluate the effects of fisetin, a senolytic flavonoid compound, on lung function and biomarkers of cellular senescence in older adults aged 60 years and older. Participants will include individuals with a history of at least 10 pack-years of smoking as well as age-matched never-smokers. Forty participants will be randomized to receive either fisetin or placebo using a short-course \"hit-and-run\" dosing strategy (approximately 20 mg\u002Fkg\u002Fday orally for 2 consecutive days on Days 1-2 and Days 8-9).",[78],"Age-Related Lung Function Decline",[80,81,82,83,84,85],"Aging","Cellular Senescence","Healthy Aging","Smoking-Related Lung Function Decline","Pulmonary Function","Smoking","2026-06-30",{"date":88,"type":89},"2026-07-01","ACTUAL",{"date":91,"type":89},"2026-06-17",{"date":93,"type":72},"2027-07-15",{"name":5,"class":6},1]